Skip to main content

Table 3 Eradication strategies

From: An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis

Patient Duration of infection prior to treatment Induction Consolidation
   Treatment Duration Treatment Duration
Successful eradication
16 (Corral, 2008) [10] Unknown – lived in BVI Meropenem 2 g tds 19 days TMP/SMX 960 mg bd 19 days
Minocycline 100 mg bd
Minocycline 100 mg bd
Tobramycin (neb)a 80 mg bd
20 (O’Sullivan, 2011) [13] 3 months Imipenem 14 days Meropenem (neb) 28 days
Ceftazidime TMP/SMX 960 mg bd 2 years
4 (Visca, 2001) [15] 12 months Ceftazidime 42 days TMP/SMX 960 mg bd 210 days
TMP/SMX 960 mg bd Doxycycline
Chloramphenicol
13 (Asiah, 2006) [8] 12 months Ceftazidime 56 days TMP/SMX 960 mg bd 112 days
TMP/SMX 960 mg bd Doxycycline
22 (Radhakrishna, 2014) [17] 7 years Meropenem 2 g tds Approx 56 days Doxycycline followed by amoxycillin/clavulanic acid (doxycycline allergy) 12 months
Ceftazidime 3 g tds
Tobramycin (neb) 80 mg bd
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 1 Unknown Ceftazidime 14 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 2 1 month Ceftazidime 21 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
9 (Holland, 2002) [16] Infection 3 1-2 months Ceftazidime 14 days TMP/SMX 960 mg bd 90 days
TMP/SMX 960 mg bd
Failed Eradication
8 (O’Carroll, 2003) [12] 4 months Meropenem 2 g tds 56 days None  
Ceftazidime 3 g tds
17 6-12 months Ceftazidime 3 g tds 14 days TMP/SMX 960 mg bd 84 days
TMP/SMX 960 mg bd
23 >10 months Ceftazidime 3 g tds 21 days Unknown (patient moved to Malaysia)  
TMP/SMX 960 mg bd
Tobramycin 5 mg/kg
3 (Schülin, 2001) [14] 6 years Unspecified antipseudomonal antibiotics 14 days No (exacerbations directed against PsA)  
14 (Barth, 2007) [9] >18 months Pipracillin/clavulanate 21 days Meropenem 2 g tds 21 days
Tobramycin 5 mg/kg Ceftazidime 3 g tds
Amikacin
TMP/SMX 960 mg bd
15 >8 years Meropenem 2 g tds 14 days TMP/SMX 960 mg bd 126 days
Tobramycin Minocycline 100 mg bd
Meropenem (neb)
18 (1st attempt) 2 months Ceftazidime 1.5 g tds 14 days Infection not cleared therefore 2nd course of IV antibiotics  
Tobramycin 300 mg
Amoxycillin/Clavulanic acid 900 mg
18 (2nd attempt) 2 months Meropenem 84 days TMP/SMX 960 mg bd Long term
Ceftazidime Doxycycline
Amoxycillin/Clavulanic acid
6 (Holland, 2002) [16] >4 years Ceftazidime 50 mg/kg 120 days None (exacerbations directed against B. pseudomallei)  
Piperacillin 50 mg/kg
Amoxycillin/Clavulanic acid
7 (Holland, 2002) [16] >5 years    TMP/SMX 960 mg bd 4 years
1st isolation
7 (Holland, 2002) [16] >9 years Imipenem 20 days TMP/SMX 960 mg bd 19 days
2nd isolation Piperacillin/Clavulanic acid 42 days Tetracycline 30 days
Meropenem/TMP/SMX >30 days
11 (Holland, 2002) [16] 3 months Ceftazidime 14 days TMP/SMX 960 mg bd 330 days
Tobramycin
21 1 month Meropenem 2 g tds 42 days Tobramycin (neb) 300 mg bd 42 days
Ceftazidime 3 g tds TMP/SMX 960 mg bd
Tobramycin 7 mg/kg
  1. Success of eradication for patient 24 and patient 25 unknown
  2. aneb = nebulized
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us